SCHEMBL4580254

SCHEMBL4580254

CNC(=O)c1ccc2cncc(-c3ccc(C(N)=O)s3)c2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 9/20 0.50
CDK8 P49336 9/20 0.50
KDM4E B2RXH2 4/20 0.36
HPGD P15428 4/20 0.36
NPC1 O15118 3/20 0.36
ALDH1A1 P00352 3/20 0.36
RAB9A P51151 3/20 0.36
CSNK2A1 P68400 2/20 0.36
IKBKB O14920 1/20 0.35
MAPT P10636 2/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SCN10A Q9Y5Y9 2/20 0.33
PIP5K1C O60331 1/20 0.33
PIK3CA P42336 1/20 0.33
PI4KA P42356 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4581556 0.92 CCNC (0.53) CCNCCDK8KDM4EHPGDNPC1
SCHEMBL4580001 0.89 CCNC (0.51) CCNCCDK8KDM4EHPGDNPC1
Hydrochloric Acid SCHEMBL4581072 0.88 CCNC (0.50) CCNCCDK8KDM4EHPGDNPC1
SCHEMBL4581068 0.88 CCNC (0.50) CCNCCDK8KDM4EHPGDNPC1
SCHEMBL14287324 0.81 CCNC (0.49) CCNCCDK8HPGD
SCHEMBL14286998 0.80 CCNC (0.48) CCNCCDK8SCN10APIP5K1CPIK3CA
SCHEMBL14286988 0.78 CCNC (0.48) CCNCCDK8SCN10APIP5K1CPIK3CA
SCHEMBL4579213 0.76 CCNC (0.48) CCNCCDK8KDM4EHPGDNPC1
SCHEMBL4580883 0.75 MEN1 (0.52) CCNCCDK8KDM4EALDH1A1RAB9A
SCHEMBL4579997 0.74 KDM4E (0.41) CCNCCDK8KDM4EHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US claimed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US claimed
EP-1773834-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES Serenex, Inc. (US) 2007-04-18 EP claimed
WO-2006017672-A2 2, 8-DISUBSTITUTED NAPHTHYRIDINE DERIVATIVES SERENEX INC. (US) 2006-02-16 WO claimed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US claimed
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US disclosed
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives SERENEX, INC. 2008-02-07 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed
US-7282506-B2 2,8-disubstituted naphthyridine derivatives SERENEX, INC. (US) 2007-10-16 US disclosed
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives SERENEX, INC. 2006-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030584-A1 2,8-Disubstituted naphthyridine derivatives CCNA1, FOXM1, CCNA2 CCNC 289/4885CDK8 516/4885KDM4E 3744/4885
US-20080032991-A1 2, 8-disubstituted Naphthyridine Derivatives CCNA1, FOXM1, CCNA2 CCNC 289/4885CDK8 516/4885KDM4E 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.